Life sciences investor active in later-stage biotech rounds.
Profile being verified
What they look for
Existing investor in FoRx Therapeutics and Nouscom; participating in the Series B of Vaderis Therapeutics.
Recent investments
Recorded Swiss rounds: FoRx Therapeutics (Series A, USD 50 M, December 2025), Vaderis Therapeutics (Series B, USD 152 M, August 2026), Nouscom (Series C, USD 135 M, October 2026).
Rounds tracked by FundSwiss
- NouscomSeries C and later · USD 135 M
- Vaderis TherapeuticsSeries B · USD 152 M
- FoRx TherapeuticsSeries A · USD 50 M